Efficacy of nucleotides/nucleosides in preventing virus reactivation in tumor patients with HBV infection after chemotherapy: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

ZHAO Yuqing ^1,2 , SONG Yingying ² , YANG Yidian ^1,2 ,  ZHANG Liping ^1,2

1. Beijing University of Chinese Medicine, Beijing 100029, P.R.China;
2. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R.China;

Corresponding?author：

ZHANG Liping, Email: lpzhang2005@126.com

Keywords：

Cancer patients; Hepatitis B virus; Reactivation; Nucleotides/Nucleosides; Randomized controlled trial; Network meta-analysis

DOI：

10.7507/1672-2531.202106160

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy of different nucleosides (acids) in preventing hepatitis B virus reactivation after chemotherapy in cancer patients. Methods The Cochrane Library, PubMed, EMbase, Web of Science, CNKI, WanFang Data, and VIP databases were electronically searched to collect randomized controlled trials (RCTs) of different nucleosides (acids) to prevent HBV reactivation after chemotherapy in cancer patients from inception to June 7^th, 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Network meta-analysis was then performed by using Stata 16.0 software. Results A total of 43 RCTs involving 3 269 patients were included. There were 7 interventions, namely entecavir (ETV), lamivudine (LAM), adefovir dipivoxil (ADV), telbivudine (LdT), tenofovir dipivoxil (TDF), lamivudine combined with entecavir (LAM+ETV), and lamivudine combined with adefovir dipivoxil (LAM+ADV). The results of network meta-analysis showed that the efficacy of reducing the reactivation rate of ETV, LAM, ADV, LdT, TDF, LAM+ETV, LAM+ADV were superior than the control group. The ETV, LAM and ADV were not as effective as LAM+ETV. The leading drug combinations were LAM+ETV (94.8%), LdT (81.5%) and LA+ADV (58.0%). Conclusions Current evidence shows that LAM+ETV, LdT, and LA+ADV are more effective in preventing hepatitis B virus reactivation after chemotherapy in cancer patients. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.

Citation： ZHAO Yuqing, SONG Yingying, YANG Yidian, ZHANG Liping. Efficacy of nucleotides/nucleosides in preventing virus reactivation in tumor patients with HBV infection after chemotherapy: a network meta-analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(11): 1269-1277. doi: 10.7507/1672-2531.202106160 Copy

1.	Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med, 2016, 164(1): 30-40.
2.	王貴強, 王福生, 莊輝, 等. 慢性乙型肝炎防治指南(2019年版). 中國病毒病雜志, 2020, 10(1): 1-25.
3.	馬軍, 秦叔逵, 繆曉輝, 等. 淋巴瘤免疫化療HBV再激活預防和治療中國專家共識. 臨床腫瘤學雜志, 2013, 18(10): 935-942.
4.	中華醫學會血液學分會, 中國抗癌協會淋巴瘤專業委員會, 中華醫學會肝病學分會. 中國淋巴瘤合并HBV感染患者管理專家共識. 中華血液學雜志, 2013, 34(11): 988-993.
5.	李夢苑, 葉傳濤, 張穎, 等. HBV復制再激活研究進展. 臨床肝膽病雜志, 2017, 33(4): 751-756.
6.	Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 2009, 27(4): 605-611.
7.	Svicher V, Salpini R, Malagnino V, et al. New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts. Viruses, 2019, 11(9): 783.
8.	Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol, 2016, 64(Suppl 1): S60-S70.
9.	Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017, 152(6): 1297-1309.
10.	He L, Liu X, Zhao Y, et al. Efficacy of nucleot(s)ide analogs therapy in patients with unresectable hbv-related hepatocellular carcinoma: a systematic review and meta-analysis. Dis Markers, 2017, 2017: 7075935.
11.	劉宗財, 駱文靜, 孫冠超, 等. 恩替卡韋在核苷酸類似物中治療慢性乙型肝炎的療效. 醫學食療與健康, 2021, 19(7): 49-50.
12.	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
13.	Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6(3): 531-561.
14.	Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
15.	Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 2000, 62(3): 299-307.
16.	Chess LE, Gagnier J. Risk of bias of randomized controlled trials published in orthopaedic journals. BMC Med Res Methodol, 2013, 13: 76.
17.	Higgins JP, Altman DG, G?tzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
18.	李賡, 高健全. 抗病毒治療對鼻咽癌合并HBsAg陽性患者乙肝病毒再激活的預防效果探究. 中國地方病防治雜志, 2019, 34(3): 328-330.
19.	Liu WP, Xiao XB, Xue M, et al. Prophylactic use of entecavir for lymphoma patients with past hepatitis B virus infection: a randomized controlled trial. Clin Lymphoma Myeloma Leuk, 2019, 19(2): 103-108.
20.	占國清, 譚華炳, 李芳, 等. 恩替卡韋抗病毒對TACE治療的HBV DNA陰性乙型肝炎相關性肝癌的影響. 實用肝臟病雜志, 2018, 21(1): 96-99.
21.	張叢叢, 索曉慧, 孫國鋒, 等. 乙型肝炎表面抗原陰性的非霍奇金淋巴瘤患者化療后乙型肝炎病毒再激活的影響因素分析. 癌癥進展, 2018, 16(7): 905-907.
22.	Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg, 2018, 268(6): 943-954.
23.	龔文鋒, 陸世東, 鐘鑒宏, 等. 術前抗病毒治療對HBV-DNA陰性肝細胞癌患者術后病毒再激活及肝功能的影響. 中國腫瘤臨床, 2016, 43(15): 668-673.
24.	任慶, 熊銳華, 田秀榮, 等. 拉米夫定預防鼻咽癌合并HBV陽性患者化療中肝功能損害. 現代腫瘤醫學, 2016, 24(3): 383-386.
25.	鄭亮, 陸海軍. 肺癌并HBV攜帶者化療同時應用恩替卡韋的效果. 齊魯醫學雜志, 2016, 31(1): 4-5,9.
26.	王凱, 蔣國民, 田豐, 等. 恩替卡韋聯合肝動脈化療栓塞治療HBV-DNA陰性HBV相關性肝癌患者的臨床研究. 中華肝膽外科雜志, 2015, 21(11): 738-740.
27.	吳娜. 恩替卡韋治療非霍奇金淋巴瘤合并乙肝病毒感染的療效觀察. 醫學信息, 2015, (34): 102-102.
28.	譚英. HBsAg陽性者胃癌術后化療后再激活的臨床分析. 江西醫藥, 2014, 49(1): 53-55.
29.	Huang L, Li J, Yan J, et al. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat, 2013, 20(5): 336-342.
30.	任莉. 拉米夫定預防性治療非霍奇金淋巴瘤合并乙型肝炎病毒感染再激活的臨床觀察. 中國醫師進修雜志, 2012, 35(13): 61-63.
31.	Long M, Jia W, Li S, et al. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy. Breast Cancer Res Treat, 2011, 127(3): 705-712.
32.	許多, 馬牧松, 李丹丹. 化療對合并慢性乙型肝炎的乳腺癌患者肝功能及HBV DNA的影響. 吉林醫學, 2010, 31(23): 3842-3843.
33.	段林燦, 李高峰, 張勇, 等. 合并HBV非小細胞肺癌化療同時使用抗病毒治療的臨床應用. 中國肺癌雜志, 2009, 12(8): 893-895.
34.	Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 2006, 43(2): 233-240.
35.	鄭亮, 陸海軍. 肺癌并發乙型肝炎病毒攜帶者化療同時應用恩替卡韋的效果. 泰山醫學院學報, 2018, 39(5): 509-512.
36.	陳慧華, 梁嶸, 文玲波, 等. 恩替卡韋在實體腫瘤化療中預防乙型肝炎病毒再激活臨床研究. 腫瘤藥學, 2017, 7(1): 79-82.
37.	戴鋒, 付守忠, 王斌, 等. 核苷類藥物聯合肝動脈栓塞化療在肝癌中應用觀察. 交通醫學, 2013, (3): 272-274.
38.	莊見齊. 替比夫定預防放(化)療后乙肝再激活臨床觀察. 河北醫學, 2009, 15(5): 537-539.
39.	孫杰, 姜麗娜, 潘賽英. 拉米夫定對HBV-DNA陽性惡性腫瘤患者化療所致HBV再激活的預防作用評價. 現代腫瘤醫學, 2012, 20(9): 1932-1935.
40.	吳國武, 黃鎮, 楊權烈. 拉米夫定在感染乙型肝炎病毒腫瘤患者化療中的應用. 廣東醫學, 2012, 33(17): 2660-2661.
41.	李春霞. 恩替卡韋防治血液腫瘤化療后乙肝病毒再激活的臨床研究. 臨床醫學, 2014, 34(4): 26-28.
42.	王建平, 漆龍飛, 盧鵬, 等. 乙肝病毒陽性實體瘤患者化療期間預防性抗病毒治療療效觀察. 現代診斷與治療, 2014, (11): 2424-2425.
43.	楊永健, 宋輝. 拉米夫定預防非霍奇金淋巴瘤合并乙肝患者再激活的療效觀察. 中外醫學研究, 2016, 14(20): 34-35.
44.	Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat, 2004, 11(2): 141-147.
45.	Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One, 2017, 12(9): e0184550.
46.	熊勇, 周同沖, 張偉軍, 等. 拉米夫定預防鼻咽癌治療相關性乙肝病毒再激活的療效分析. 國際醫藥衛生導報, 2010, 16(1): 50-54.
47.	李云濤, 石琳熙. 拉米夫定對伴乙肝病毒攜帶的非霍奇金淋巴瘤患者病毒再激活的預防作用. 健康必讀(中旬刊), 2012, 11(5): 243-244.
48.	邵國良, 韓蘇陽, 陳玉堂, 等. TACE聯合拉米夫定治療HBV-DNA陽性肝癌患者的臨床研究. 浙江省醫學會放射學分會:2013年浙江省放射學學術年會論文集, 2013: 1.
49.	Ho EY, Yau T, Rousseau F, et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int, 2015, 9(2): 224-230.
50.	洪帆, 梁江萍, 秦婷婷, 等. 乳腺癌患者化療后乙肝病毒再激活及拉米夫定預防性應用的臨床研究. 現代生物醫學進展, 2015, 15(8): 1505-1508.
51.	王小波. HBV-DNA陰性的HCC患者圍手術期HBV再激活及其影響因素. 南寧: 廣西醫科大學, 2015.
52.	范璐, 劉友德, 鄒志強, 等. 恩替卡韋及拉米夫定預防NHL化療相關性HBV再激活的療效對比. 中國現代藥物應用, 2017, 11(12): 132-134.
53.	陳志剛, 劉慧君, 陳季紅, 等. 恩替卡韋聯合拉米夫定對腫瘤并乙肝病毒感染患者化療后乙肝病毒再激活的預防作用研究. 保健文匯, 2019, (7): 247-248.
54.	羅方杰. 恩替卡韋聯合拉米夫定對腫瘤并乙肝病毒感染患者化療后乙肝病毒再激活的預防作用. 臨床合理用藥雜志, 2017, 10(9): 75-77.
55.	Wang K, Jiang G, Jia Z, et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine (Baltimore), 2018, 97(22): e10940.
56.	邱華平, 李鷹飛, 查國華. 恩替卡韋對腫瘤化療合并乙肝病毒感染患者乙肝病毒再激活和對肝功能的影響. 現代診斷與治療, 2019, 30(23): 4114-4116.
57.	胡瑞華. 抗病毒治療對乙肝病毒DNA陰性的乙肝相關肝細胞癌行TACE術后HBV再激活的預防及預后影響. 現代診斷與治療, 2017, 28(22): 4268-4269.
58.	Toka B, Koksal AS, Eminler AT, et al. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. Dig Dis Sci, 2021, 66(7): 2417-2426.
59.	Cai Q, Chen K, Zhong G, et al. Prophylactic lamivudine plus adefovir dipivoxil versus lamivudine in preventing HBV reactivation in hbsagpositive lymphoma patients after chemotherapy. Hematol Oncol, 2015, 33(3): 10.
60.	Siregar L, Waspodo AS, Nadliroh S, et al. A pilot study to explore the use of telbivudine and lamivudine to prevent chemotherapy-related reactivation of hepatitis B infection. Hepatol Int, 2018, 12(2): S339.
61.	Zheng JN, Zou TT, Zou H, et al. Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther, 2016, 14(10): 979-987.
62.	譚英, 吳惠芳, 鄒萌麗, 等. 拉米夫定及恩替卡韋治療非何杰金淋巴瘤相關性HBV再激活的對照研究. 江西醫藥, 2014, (9): 854-856,857.
63.	Yoo JJ, Kim HY, Lee JH, et al. Comparison of lamivudine, telbivudine, and entecavir as antiviral prophylaxis for patients with Hepatitis B undergoing cytotoxic chemotherapy. Hepatology, 2012, 56: 631A.
64.	魯燕, 劉凱強, 任玨輝. 肝龍膠囊聯合拉米夫定治療慢性乙型肝炎的臨床研究. 現代藥物與臨床, 2018, 33(12): 3306-3311.
65.	李思維, 白雪, 何卓凱, 等. 恩替卡韋預防鼻咽癌治療中乙肝病毒再激活的臨床研究. 中國藥房, 2016, 27(11): 1507-1510.
66.	Tseng CM, Chen TB, Hsu YC, et al. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol, 2016, 12(4): 421-429.
67.	鄭亮. 抗病毒干預對肺癌合并乙型肝炎病毒攜帶者化療后肝功能的影響分析. 青島: 青島大學, 2020.
68.	An P, Bian L, Yin B, et al. Risk factors of gene-resistant mutations in different nucleosides. Hepatogastroenterology, 2012, 59(113): 228-230.
69.	van B?mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 2010, 51(1): 73-80.
70.	徐文棟. 替比夫定與恩替卡韋治療HBeAg陽性慢性乙型肝炎的對比研究. 科學咨詢(科技管理), 2021, (5): 88-89.
71.	Chan HL, Shaikh J, Gupta S, et al. Renal Function in nucleos(t)ide analog-treated patients with chronic hepatitis B: a systematic literature review and network meta-analysis. Adv Ther, 2016, 33(5): 862-875.
72.	Chen CJ, Yu HC, Chang CW, et al. Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy. Medicine (Baltimore), 2020, 99(22): e20330.
73.	張婷. 選擇一線抗病毒藥物進行治療, 為什么特別重要. 肝博士, 2021, (4): 41-42.
74.	Wani MA, Sodhi JS, Yatoo GN, et al. Clinical profile and efficacy of antivirals in hepatitis B virus reactivation, in patients with cancer receiving chemotherapy. J Clin Exp Hepatol, 2020, 10(6): 590-598.

1. Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med, 2016, 164(1): 30-40.
2. 王貴強, 王福生, 莊輝, 等. 慢性乙型肝炎防治指南(2019年版). 中國病毒病雜志, 2020, 10(1): 1-25.
3. 馬軍, 秦叔逵, 繆曉輝, 等. 淋巴瘤免疫化療HBV再激活預防和治療中國專家共識. 臨床腫瘤學雜志, 2013, 18(10): 935-942.
4. 中華醫學會血液學分會, 中國抗癌協會淋巴瘤專業委員會, 中華醫學會肝病學分會. 中國淋巴瘤合并HBV感染患者管理專家共識. 中華血液學雜志, 2013, 34(11): 988-993.
5. 李夢苑, 葉傳濤, 張穎, 等. HBV復制再激活研究進展. 臨床肝膽病雜志, 2017, 33(4): 751-756.
6. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 2009, 27(4): 605-611.
7. Svicher V, Salpini R, Malagnino V, et al. New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts. Viruses, 2019, 11(9): 783.
8. Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol, 2016, 64(Suppl 1): S60-S70.
9. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017, 152(6): 1297-1309.
10. He L, Liu X, Zhao Y, et al. Efficacy of nucleot(s)ide analogs therapy in patients with unresectable hbv-related hepatocellular carcinoma: a systematic review and meta-analysis. Dis Markers, 2017, 2017: 7075935.
11. 劉宗財, 駱文靜, 孫冠超, 等. 恩替卡韋在核苷酸類似物中治療慢性乙型肝炎的療效. 醫學食療與健康, 2021, 19(7): 49-50.
12. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
13. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6(3): 531-561.
14. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
15. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 2000, 62(3): 299-307.
16. Chess LE, Gagnier J. Risk of bias of randomized controlled trials published in orthopaedic journals. BMC Med Res Methodol, 2013, 13: 76.
17. Higgins JP, Altman DG, G?tzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
18. 李賡, 高健全. 抗病毒治療對鼻咽癌合并HBsAg陽性患者乙肝病毒再激活的預防效果探究. 中國地方病防治雜志, 2019, 34(3): 328-330.
19. Liu WP, Xiao XB, Xue M, et al. Prophylactic use of entecavir for lymphoma patients with past hepatitis B virus infection: a randomized controlled trial. Clin Lymphoma Myeloma Leuk, 2019, 19(2): 103-108.
20. 占國清, 譚華炳, 李芳, 等. 恩替卡韋抗病毒對TACE治療的HBV DNA陰性乙型肝炎相關性肝癌的影響. 實用肝臟病雜志, 2018, 21(1): 96-99.
21. 張叢叢, 索曉慧, 孫國鋒, 等. 乙型肝炎表面抗原陰性的非霍奇金淋巴瘤患者化療后乙型肝炎病毒再激活的影響因素分析. 癌癥進展, 2018, 16(7): 905-907.
22. Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg, 2018, 268(6): 943-954.
23. 龔文鋒, 陸世東, 鐘鑒宏, 等. 術前抗病毒治療對HBV-DNA陰性肝細胞癌患者術后病毒再激活及肝功能的影響. 中國腫瘤臨床, 2016, 43(15): 668-673.
24. 任慶, 熊銳華, 田秀榮, 等. 拉米夫定預防鼻咽癌合并HBV陽性患者化療中肝功能損害. 現代腫瘤醫學, 2016, 24(3): 383-386.
25. 鄭亮, 陸海軍. 肺癌并HBV攜帶者化療同時應用恩替卡韋的效果. 齊魯醫學雜志, 2016, 31(1): 4-5,9.
26. 王凱, 蔣國民, 田豐, 等. 恩替卡韋聯合肝動脈化療栓塞治療HBV-DNA陰性HBV相關性肝癌患者的臨床研究. 中華肝膽外科雜志, 2015, 21(11): 738-740.
27. 吳娜. 恩替卡韋治療非霍奇金淋巴瘤合并乙肝病毒感染的療效觀察. 醫學信息, 2015, (34): 102-102.
28. 譚英. HBsAg陽性者胃癌術后化療后再激活的臨床分析. 江西醫藥, 2014, 49(1): 53-55.
29. Huang L, Li J, Yan J, et al. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat, 2013, 20(5): 336-342.
30. 任莉. 拉米夫定預防性治療非霍奇金淋巴瘤合并乙型肝炎病毒感染再激活的臨床觀察. 中國醫師進修雜志, 2012, 35(13): 61-63.
31. Long M, Jia W, Li S, et al. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy. Breast Cancer Res Treat, 2011, 127(3): 705-712.
32. 許多, 馬牧松, 李丹丹. 化療對合并慢性乙型肝炎的乳腺癌患者肝功能及HBV DNA的影響. 吉林醫學, 2010, 31(23): 3842-3843.
33. 段林燦, 李高峰, 張勇, 等. 合并HBV非小細胞肺癌化療同時使用抗病毒治療的臨床應用. 中國肺癌雜志, 2009, 12(8): 893-895.
34. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 2006, 43(2): 233-240.
35. 鄭亮, 陸海軍. 肺癌并發乙型肝炎病毒攜帶者化療同時應用恩替卡韋的效果. 泰山醫學院學報, 2018, 39(5): 509-512.
36. 陳慧華, 梁嶸, 文玲波, 等. 恩替卡韋在實體腫瘤化療中預防乙型肝炎病毒再激活臨床研究. 腫瘤藥學, 2017, 7(1): 79-82.
37. 戴鋒, 付守忠, 王斌, 等. 核苷類藥物聯合肝動脈栓塞化療在肝癌中應用觀察. 交通醫學, 2013, (3): 272-274.
38. 莊見齊. 替比夫定預防放(化)療后乙肝再激活臨床觀察. 河北醫學, 2009, 15(5): 537-539.
39. 孫杰, 姜麗娜, 潘賽英. 拉米夫定對HBV-DNA陽性惡性腫瘤患者化療所致HBV再激活的預防作用評價. 現代腫瘤醫學, 2012, 20(9): 1932-1935.
40. 吳國武, 黃鎮, 楊權烈. 拉米夫定在感染乙型肝炎病毒腫瘤患者化療中的應用. 廣東醫學, 2012, 33(17): 2660-2661.
41. 李春霞. 恩替卡韋防治血液腫瘤化療后乙肝病毒再激活的臨床研究. 臨床醫學, 2014, 34(4): 26-28.
42. 王建平, 漆龍飛, 盧鵬, 等. 乙肝病毒陽性實體瘤患者化療期間預防性抗病毒治療療效觀察. 現代診斷與治療, 2014, (11): 2424-2425.
43. 楊永健, 宋輝. 拉米夫定預防非霍奇金淋巴瘤合并乙肝患者再激活的療效觀察. 中外醫學研究, 2016, 14(20): 34-35.
44. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat, 2004, 11(2): 141-147.
45. Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One, 2017, 12(9): e0184550.
46. 熊勇, 周同沖, 張偉軍, 等. 拉米夫定預防鼻咽癌治療相關性乙肝病毒再激活的療效分析. 國際醫藥衛生導報, 2010, 16(1): 50-54.
47. 李云濤, 石琳熙. 拉米夫定對伴乙肝病毒攜帶的非霍奇金淋巴瘤患者病毒再激活的預防作用. 健康必讀(中旬刊), 2012, 11(5): 243-244.
48. 邵國良, 韓蘇陽, 陳玉堂, 等. TACE聯合拉米夫定治療HBV-DNA陽性肝癌患者的臨床研究. 浙江省醫學會放射學分會:2013年浙江省放射學學術年會論文集, 2013: 1.
49. Ho EY, Yau T, Rousseau F, et al. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int, 2015, 9(2): 224-230.
50. 洪帆, 梁江萍, 秦婷婷, 等. 乳腺癌患者化療后乙肝病毒再激活及拉米夫定預防性應用的臨床研究. 現代生物醫學進展, 2015, 15(8): 1505-1508.
51. 王小波. HBV-DNA陰性的HCC患者圍手術期HBV再激活及其影響因素. 南寧: 廣西醫科大學, 2015.
52. 范璐, 劉友德, 鄒志強, 等. 恩替卡韋及拉米夫定預防NHL化療相關性HBV再激活的療效對比. 中國現代藥物應用, 2017, 11(12): 132-134.
53. 陳志剛, 劉慧君, 陳季紅, 等. 恩替卡韋聯合拉米夫定對腫瘤并乙肝病毒感染患者化療后乙肝病毒再激活的預防作用研究. 保健文匯, 2019, (7): 247-248.
54. 羅方杰. 恩替卡韋聯合拉米夫定對腫瘤并乙肝病毒感染患者化療后乙肝病毒再激活的預防作用. 臨床合理用藥雜志, 2017, 10(9): 75-77.
55. Wang K, Jiang G, Jia Z, et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine (Baltimore), 2018, 97(22): e10940.
56. 邱華平, 李鷹飛, 查國華. 恩替卡韋對腫瘤化療合并乙肝病毒感染患者乙肝病毒再激活和對肝功能的影響. 現代診斷與治療, 2019, 30(23): 4114-4116.
57. 胡瑞華. 抗病毒治療對乙肝病毒DNA陰性的乙肝相關肝細胞癌行TACE術后HBV再激活的預防及預后影響. 現代診斷與治療, 2017, 28(22): 4268-4269.
58. Toka B, Koksal AS, Eminler AT, et al. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. Dig Dis Sci, 2021, 66(7): 2417-2426.
59. Cai Q, Chen K, Zhong G, et al. Prophylactic lamivudine plus adefovir dipivoxil versus lamivudine in preventing HBV reactivation in hbsagpositive lymphoma patients after chemotherapy. Hematol Oncol, 2015, 33(3): 10.
60. Siregar L, Waspodo AS, Nadliroh S, et al. A pilot study to explore the use of telbivudine and lamivudine to prevent chemotherapy-related reactivation of hepatitis B infection. Hepatol Int, 2018, 12(2): S339.
61. Zheng JN, Zou TT, Zou H, et al. Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther, 2016, 14(10): 979-987.
62. 譚英, 吳惠芳, 鄒萌麗, 等. 拉米夫定及恩替卡韋治療非何杰金淋巴瘤相關性HBV再激活的對照研究. 江西醫藥, 2014, (9): 854-856,857.
63. Yoo JJ, Kim HY, Lee JH, et al. Comparison of lamivudine, telbivudine, and entecavir as antiviral prophylaxis for patients with Hepatitis B undergoing cytotoxic chemotherapy. Hepatology, 2012, 56: 631A.
64. 魯燕, 劉凱強, 任玨輝. 肝龍膠囊聯合拉米夫定治療慢性乙型肝炎的臨床研究. 現代藥物與臨床, 2018, 33(12): 3306-3311.
65. 李思維, 白雪, 何卓凱, 等. 恩替卡韋預防鼻咽癌治療中乙肝病毒再激活的臨床研究. 中國藥房, 2016, 27(11): 1507-1510.
66. Tseng CM, Chen TB, Hsu YC, et al. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol, 2016, 12(4): 421-429.
67. 鄭亮. 抗病毒干預對肺癌合并乙型肝炎病毒攜帶者化療后肝功能的影響分析. 青島: 青島大學, 2020.
68. An P, Bian L, Yin B, et al. Risk factors of gene-resistant mutations in different nucleosides. Hepatogastroenterology, 2012, 59(113): 228-230.
69. van B?mmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 2010, 51(1): 73-80.
70. 徐文棟. 替比夫定與恩替卡韋治療HBeAg陽性慢性乙型肝炎的對比研究. 科學咨詢(科技管理), 2021, (5): 88-89.
71. Chan HL, Shaikh J, Gupta S, et al. Renal Function in nucleos(t)ide analog-treated patients with chronic hepatitis B: a systematic literature review and network meta-analysis. Adv Ther, 2016, 33(5): 862-875.
72. Chen CJ, Yu HC, Chang CW, et al. Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy. Medicine (Baltimore), 2020, 99(22): e20330.
73. 張婷. 選擇一線抗病毒藥物進行治療, 為什么特別重要. 肝博士, 2021, (4): 41-42.
74. Wani MA, Sodhi JS, Yatoo GN, et al. Clinical profile and efficacy of antivirals in hepatitis B virus reactivation, in patients with cancer receiving chemotherapy. J Clin Exp Hepatol, 2020, 10(6): 590-598.

Previous Article
Safety of low-molecular-weight heparin in pregnancy: a systematic review
Next Article
Efficacy and safety of second-line medications for status epilepticus: a network meta-analysis

Chinese Journal of Evidence-Based Medicine

Efficacy of nucleotides/nucleosides in preventing virus reactivation in tumor patients with HBV infection after chemotherapy: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content